[Skip to Content]
[Skip to Content Landing]
Views 664
Citations 0
Invited Commentary
June 27, 2019

Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges

Author Affiliations
  • 1The Holden Comprehensive Cancer Center, Department of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City
  • 2Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California
  • 3Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City
JAMA Oncol. 2019;5(8):1167-1169. doi:10.1001/jamaoncol.2019.1008

Abiraterone acetate, 1000 mg, once daily is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and high-risk metastatic castration-sensitive prostate cancer (mCSPC) in combination with prednisone, 5 mg, orally twice daily or once daily, respectively.1 However, the ideal dose of prednisone combined with abiraterone acetate is not known. In this issue of JAMA Oncology, Attard and colleagues2 report on the safety results of a phase 2 study of abiraterone acetate in combination with 4 different glucocorticoid regimens in the mCRPC setting.

×